UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia

European journal of clinical pharmacology, 2024, Vol.80 (1), p.105-113

2024

Link zum Volltext

Verfügbarkeit prüfen

Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition

Cancer research (Chicago, Ill.), 2018-05, Vol.78 (10), p.2721-2731

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting Checkpoint Kinase 1 in Cancer Therapeutics

Clinical cancer research, 2007-04, Vol.13 (7), p.1955-1960

2007

Link zum Volltext

Verfügbarkeit prüfen

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Molecular cancer therapeutics, 2008-09, Vol.7 (9), p.2955-2966

2008

Link zum Volltext

Verfügbarkeit prüfen

Aurora Kinases: New Targets for Cancer Therapy

Clinical cancer research, 2006-12, Vol.12 (23), p.6869-6875

2006

Link zum Volltext

Verfügbarkeit prüfen

Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study

Cancer, 2024-06, Vol.130 (11), p.1991-2002

2024

Link zum Volltext

Verfügbarkeit prüfen

Tumor growth inhibition‐overall survival modeling in non‐small cell lung cancer: A case study from GEMSTONE‐302

CPT: pharmacometrics and systems pharmacology, 2024-03, Vol.13 (3), p.437-448

2024

Link zum Volltext

Verfügbarkeit prüfen

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST

Journal of clinical oncology, 2020-08, Vol.38 (23), p.2667-2676

2020

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer

British journal of cancer, 2023-11, Vol.129 (10), p.1608-1618

2023

Link zum Volltext

Verfügbarkeit prüfen

Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Journal of clinical oncology, 2006-11, Vol.24 (33), p.5201-5206

2006

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

Journal of clinical oncology, 2005-03, Vol.23 (9), p.1803-1810

2005

Link zum Volltext

Verfügbarkeit prüfen

Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780

Molecular biology of the cell, 2009-04, Vol.20 (8), p.2218-2228

2009

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors

Clinical cancer research, 2008-10, Vol.14 (20), p.6704-6711

2008

Link zum Volltext

Verfügbarkeit prüfen

CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo

Clinical cancer research, 2007-01, Vol.13 (2), p.591-602

2007

Link zum Volltext

Verfügbarkeit prüfen

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

Cell cycle (Georgetown, Tex.), 2010-03, Vol.9 (5), p.995-1004

2010

Link zum Volltext

Verfügbarkeit prüfen

Can a propensity score matching method be applied to assessing efficacy from single-arm proof-of-concept trials in oncology?

CPT: pharmacometrics and systems pharmacology, 2023-09, Vol.12 (9), p.1347-1357

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2015-08, Vol.33 (24), p.2609-2616

2015

Link zum Volltext

Verfügbarkeit prüfen

Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe

Cancer research (Chicago, Ill.), 2004-09, Vol.64 (18), p.6635-6644

2004

Link zum Volltext

Verfügbarkeit prüfen

Abstract B1: Gene expression and TP53 mutation analysis predict sensitivity of leukemia cells to MDM2 inhibition by DS-3032b

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B1-B1

2015

Link zum Volltext

Verfügbarkeit prüfen

phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies

Cancer chemotherapy and pharmacology, 2009-10, Vol.64 (5), p.935-944

2009

Link zum Volltext

Verfügbarkeit prüfen

Oncology phase II proof‐of‐concept studies with multiple targets: Randomized controlled trial or single arm?

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2020-03, Vol.19 (2), p.117-125

2020

Link zum Volltext

Verfügbarkeit prüfen

Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16191-e16191

2022

Link zum Volltext

Verfügbarkeit prüfen

A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development

Contemporary clinical trials, 2018-01, Vol.64, p.238-242

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4759: Designing clinical trials in tumor indications with a positive signal in phase 1

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4759-4759

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract B5: Preclinical characterization of a novel orally-available MDM2 inhibitor DS-3032b: Anti-tumor profile and predictive biomarkers for sensitivity

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B5-B5

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(52)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Humans
(23)
Oncology
(21)
Biological And Medical Sciences
(11)
Medical Sciences
(10)
Antineoplastic Agents
(9)
Cancer Research
(9)
Female
(9)
Male
(9)
Tumors
(9)
Aged
(8)
Animals
(8)
Middle Aged
(8)
Pharmacology & Pharmacy
(8)
Pharmacology. Drug Treatments
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Camptothecin - Analogs & Derivatives
(6)
Dose-Response Relationship, Drug
(6)
Mice
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia

Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition

Targeting Checkpoint Kinase 1 in Cancer Therapeutics

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Aurora Kinases: New Targets for Cancer Therapy

Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study

Tumor growth inhibition‐overall survival modeling in non‐small cell lung cancer: A case study from GEMSTONE‐302

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer

Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780

A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors

CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

Can a propensity score matching method be applied to assessing efficacy from single-arm proof-of-concept trials in oncology?

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe

Abstract B1: Gene expression and TP53 mutation analysis predict sensitivity of leukemia cells to MDM2 inhibition by DS-3032b

phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies

Oncology phase II proof‐of‐concept studies with multiple targets: Randomized controlled trial or single arm?

Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC)

A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development

Abstract 4759: Designing clinical trials in tumor indications with a positive signal in phase 1

Abstract B5: Preclinical characterization of a novel orally-available MDM2 inhibitor DS-3032b: Anti-tumor profile and predictive biomarkers for sensitivity

Suchergebnisse filtern